Longitudinal profiling of soluble immune checkpoint proteins in oropharyngeal squamous cell carcinoma: treatment-associated dynamics and exploratory associations with disease stage and relapse-free survival
Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction Oropharyngeal squamous cell carcinoma (OPSCC) is now predominantly associated with human papillomavirus (HPV), particularly HPV16, and is characterized by a distinct immune landscape and a generally favorable prognosis. Nonetheless, a subset of patients relapses following curative treatment, emphasizing the need for biomarkers that capture dynamic systemic immune regulation beyond tissue-based analyses. Soluble immune checkpoint proteins (sICPs) are biologically active circulating mediators that may reflect the balance between anti-tumor immunity and immune tolerance. Methods In this prospective observational study, we longitudinally profiled serum levels of 17 sICPs in 77 patients with OPSCC who received curative-intent radiotherapy, with or without chemotherapy. Serum samples were collected at three time points: pre-treatment (baseline), 7 weeks after treatment initiation, and at 12 months after treatment completion, and analyzed in relation to sampling time point, tumor stage, treatment modality, and clinical outcome. Results Among 65 HPV16 + /p16 + patients, distinct treatment-associated temporal changes were observed, including a transient increase in soluble TIM-3 and a concomitant decrease in soluble PD-1 during active therapy, followed by partial recovery at long-term follow-up. At 12 months after treatment completion, soluble CD40 levels were elevated, while soluble TLR-2 levels were reduced, indicating persistent remodeling of systemic immune regulation beyond active treatment. Tumor stages II-IVA were associated with increased baseline levels of inhibitory sICPs, including soluble GITRL and soluble CTLA-4, compared with stage I, and a trend toward reduced soluble CD80 levels, suggesting a more immunosuppressive systemic milieu in advanced disease. Importantly, elevated pre-treatment soluble PD-1 was associated with poorer relapse-free survival in the entire cohort of 77 patients, although this association was not observed in the HPV16 + /p16 + subgroup alone. No other sICP retained prognostic significance after correction for multiple testing. Discussion Given the sample size and limited number of events, the association between baseline sPD-1 and RFS in the entire cohort should be regarded as hypothesis-generating. Together, these findings indicate that circulating sICPs undergo dynamic and sustained changes during and after treatment and support further investigation of their associations with systemic immune status and clinical outcomes in larger, prospectively powered OPSCC cohorts.
Source: Frontiers in Oncology
Authors: Sakellariou C.(Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing), Ajazi K.(Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – review & editing), Tiblom Ehrsson Y.(Funding acquisition, Project administration, Resources, Writing – review & editing), Laurell G.(Conceptualization, Funding acquisition, Investigation, Project administration, Supervision, Writing – review & editing), Greiff L.(Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Writing – review & editing), Lindstedt M.(Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing – review & editing)
Institutions: Lund University, Uppsala University, Skåne University Hospital
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Awards: G9001396555, G9001397200
OpenAlex ID: W7236085688
